| Management target | Revenue FY27 |
|---|
| Revenue growth | 17% YoY consolidated growth. |
|---|---|
| Margins | EBITDA margin up from 8.5% to 12.5%. |
| Order book | Healthy order inflows and RFP conversion driving CDMO growth. |
| Demand visibility | Strong RFP activity in CDMO; power brands growing at mid-teens. |
| Management confidence | High; guided for sustained momentum and margin expansion. |
Growth
Revenue grew 17% YoY to ₹2,270Cr; EBITDA margin expanded 400bps to 12.5%.
Outlook
Expects sustained revenue growth and EBITDA expansion through FY27; Kenalog supplies to start Q2FY27.
Risks
Prolonged customer decision-making timelines in CDMO; raw material inflation and supply-chain headwinds mentioned.
Investor Presentation filed with NSE, NSE: PPLPHARMA. Summary written with AI assistance from the document.
Piramal Pharma Ltd: key numbers
- Share price
- ₹202.67
- Market cap
- ₹26,982 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -86.0×Sector 47.4×
- Promoter holding
- 34.80%-0.06% QoQ
- FII holding
- 12.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Other Announcement
Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.
Piramal Pharma Business Update
Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.
Piramal Pharma Other Announcement
Piramal Pharma Limited received an improved ESG rating of 65 from NSE Sustainability Ratings and Analytics. The rating was assigned voluntarily based on public disclosures.
Piramal Pharma Share Pledge
Deutsche Bank AG, acting as security agent, has disclosed the re-creation of a pledge over 98.4 million shares of Piramal Pharma Limited by the borrower.
Piramal Pharma Business Update
Piramal Pharma Limited released its Sustainability Report for FY2025-26, detailing the company's ESG performance across key pillars, including business resilience and operational sustainability.
Piramal Pharma Merger & Restructuring Worth ₹76 Cr
Piramal Pharma acquired an additional 40.67% stake in Yapan Bio for ₹76 Crore. This transaction increases its total holding to 74%, making Yapan Bio a subsidiary.
- Value
- ₹76.00 Cr